Short Interest in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Decreases By 65.8%

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totaling 7,148 shares, a decline of 65.8% from the June 15th total of 20,871 shares. Based on an average trading volume of 29,227 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the company’s stock are sold short.

Kiora Pharmaceuticals Stock Performance

Shares of NASDAQ:KPRX opened at $2.51 on Monday. The firm has a market cap of $11.12 million, a PE ratio of -0.93 and a beta of -0.40. The company has a fifty day simple moving average of $2.58 and a 200 day simple moving average of $2.31. Kiora Pharmaceuticals has a 12-month low of $1.76 and a 12-month high of $3.29.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.58) EPS for the quarter, meeting analysts’ consensus estimates of ($0.58).

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded Kiora Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, June 26th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $10.00.

Hedge Funds Weigh In On Kiora Pharmaceuticals

Large investors have recently modified their holdings of the stock. Two Sigma Investments LP acquired a new position in Kiora Pharmaceuticals in the third quarter worth about $33,000. Renaissance Technologies LLC increased its holdings in Kiora Pharmaceuticals by 71.0% in the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock valued at $42,000 after buying an additional 8,800 shares during the last quarter. Citadel Advisors LLC bought a new stake in Kiora Pharmaceuticals in the third quarter valued at about $125,000. Alyeska Investment Group L.P. acquired a new stake in Kiora Pharmaceuticals during the fourth quarter valued at approximately $152,000. Finally, DRW Securities LLC raised its stake in Kiora Pharmaceuticals by 199.2% during the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after buying an additional 73,417 shares in the last quarter. Institutional investors own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.